Working… Menu

Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01655316
Recruitment Status : Completed
First Posted : August 1, 2012
Last Update Posted : November 14, 2012
Information provided by (Responsible Party):
Tehran University of Medical Sciences

Brief Summary:

PSVT is a common rhythm disorder in emergency department which can be recurrent in some cases.

Intravenous Adenosine is the drug of choice in PSVT control in acute settings but is a very short acting agent.

Providing a complementary medication to decrease the rate of recurrence of PSVT after its initial control will be promising.

This study evaluates the role of the oral Verapamil in recurrence control of PSVT in emergency situations.

Condition or disease Intervention/treatment Phase
Paroxysmal Supraventricular Tachycardia Drug: Verapamil Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Study Start Date : October 2010
Actual Primary Completion Date : August 2011
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Verapamil
40 mg Verapamil Per Oral
Drug: Verapamil

Primary Outcome Measures :
  1. Recurrence Control [ Time Frame: 2 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age>18 years old
  • PSVT on emergency department presentation

Exclusion Criteria:

  • Instability in hemodynamic status
  • Allergy to Verapamil

Layout table for additonal information
Responsible Party: Tehran University of Medical Sciences Identifier: NCT01655316     History of Changes
Other Study ID Numbers: 16062
First Posted: August 1, 2012    Key Record Dates
Last Update Posted: November 14, 2012
Last Verified: November 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Tachycardia, Supraventricular
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Cardiac Conduction System Disease
Pathologic Processes
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents